Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Nucala | mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucala | Mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucala | mepolizumab | Asthma, severe eosinophilic (pediatric) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Xolair | Omalizumab (Drug Plan Submission) | Asthma, severe persistent | Reimburse with clinical criteria and/or conditions | Complete | ||
Xolair | Omalizumab | Asthma, severe persistent | Cancelled | |||
Xolair | Omalizumab | Asthma, severe persistent | Do not list | Complete | ||
Myinfla | colchicine | Atherothrombotic events in coronary artery disease | Do not reimburse | Complete | ||
Dupixent | dupilumab | atopic dermatitis | Do not reimburse | Complete | ||
Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | ||
Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete |